Percorrer por autor "Sharma, Ashwani"
A mostrar 1 - 2 de 2
Resultados por página
Opções de ordenação
- Enhancing therapy with nano-based delivery systems: exploring the bioactive properties and effects of apigeninPublication . Kumar, Girish; Jain, Pushpika; Virmani, Tarun; Sharma, Ashwani; Akhtar, Md Sayeed; Aldosari, Saad A; Khan, Mohd Faiyaz; Duarte, Sofia O D; Fonte, PedroApigenin, a poten t na tural flav onoid , has emerged as a key therapeutic agent due to its multifac et ed medicinal properties in combating various diseases. How ev er, apigenin’s clinical utility is greatly limited by its poor w a ter solubility, low bioav ailabilit y and stabilit y issues. To address these challenges, this review paper explores the innov a tive field of nanotechnology-based delivery sy st ems, which have shown significant promise in improving the delivery and effectiveness of apigenin. This paper also explores the synerg istic pot ential of c o-delivering apigenin with conventional therapeutic agents. Despite the advantageous properties of these nanoformulations, critical challenges such as scalable pr oduction, r egulatory appr ovals and compr ehensiv e long-term safety assessments remain key hurdles in their clinical adoption which must be addressed for commercialization of apigenin-based formulations.
- Nanocarriers in Tuberculosis treatment: Challenges and delivery strategiesPublication . Kumar, Mahesh; Virmani, Tarun; Kumar, Girish; Deshmukh, Rohitas; Sharma, Ashwani; Duarte, Sofia; Brandão, Pedro; Fonte, PedroThe World Health Organization identifies tuberculosis (TB), caused by Mycobacterium tuberculosis, as a leading infectious killer. Although conventional treatments for TB exist, they come with challenges such as a heavy pill regimen, prolonged treatment duration, and a strict schedule, leading to multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. The rise of MDR strains endangers future TB control. Despite these concerns, the hunt for an efficient treatment continues. One breakthrough has been the use of nanotechnology in medicines, presenting a novel approach for TB treatment. Nanocarriers, such as lipid nanoparticles, nanosuspensions, liposomes, and polymeric micelles, facilitate targeted delivery of anti-TB drugs. The benefits of nanocarriers include reduced drug doses, fewer side effects, improved drug solubility, better bioavailability, and improved patient compliance, speeding up recovery. Additionally, nanocarriers can be made even more targeted by linking them with ligands such as mannose or hyaluronic acid. This review explores these innovative TB treatments, including studies on nanocarriers containing anti-TB drugs and related patents.